Zeus to offer nasal screening for resistant staph strain

RARITAN, N.J. Zeus Scientific has announced its intention to offer a rapid nasal screening test for methicillin-resistant Staphylococcus aureus. The test is based upon Zeus’ own proprietary technology utilizing the enrichment and nucleic acid amplification of a target pathogen.

The new MRSA test will enable healthcare professionals to identify carriers of this pathogen within two hours. Published studies have shown that time-to-results is critical in demonstrating a reduction in MRSA hospital infection rates.

In addition to significantly improving assay performance over other technologies in this product space, the nasal MRSA test will be offered as a low cost alternative to the two currently FDA approved MRSA products without sacrificing time to results or performance.